Reviewed by Charles C. Wykoff, MD, PhD
Take-home message: Progression to proliferative diabetic retinopathy was reduced in patients treated with fluocinolone acetonide 0.2 µg/day.
Houston—Treatment with fluocinolone acetonide 0.2 µg/day significantly reduced progression to proliferative diabetic retinopathy (PDR) in patients who were part of the FAME trials1,2 and had visual acuity loss due to diabetic macular edema (DME), according to Charles C. Wykoff, MD, PhD.
“The duration of continuous steroid exposure during the FAME trials provides a unique opportunity to address the clinical question of the effect of corticosteroids on the progression to PDR,” said Dr. Wykoff, Retina Consultants of Houston, Blanton Eye Institute and Houston Methodist Hospital, Houston.
Treatment options for DME have expanded in the past decade, with four drugs now approved by the FDA for DME:
- ranibizumab (Lucentis, Genentech)
- aflibercept (Eylea, Regeneron)
- fluocinolone acetonide (Iluvien, Alimera Sciences)
- dexamethasone (Ozurdex, Allergan)
“Through multiple phase III trials of DME in eyes with diabetic retinopathy, we’ve learned that VEGF inhibition can dramatically blunt the progression to PDR,” Dr. Wykoff said.